Who was tested and what changed
CJC-1295 Ipamorelin Research: Who Was Tested?
Healthy adults received one drug, while most work on the other used animals. No published study has given both drugs together to people.
What’s the short version of the research?
Restless sleep may have started your search. CJC-1295 Ipamorelin aims to raise a hormone your body already makes.
The growth gland under your brain makes growth hormone. Two natural messages tell that gland when to release it.
CJC-1295 copies the first message. A second message, also tied to hunger, is the one ipamorelin copies.
Human and cell studies found a bigger hormone rise from the two messages together [3][4]. A tag called DAC helps CJC-1295 attach in your blood, which keeps it circulating for days [1][5].
After ipamorelin, the pigs had a growth-hormone rise, yet the older drugs’ stress-hormone rise didn’t appear [2]. If this were my family, I’d begin with the missing test of both drugs in people.
How does each drug ask the gland to work?
CJC-1295 copies the brain’s first order to your growth gland. The order tells that gland to make and release growth hormone.
Ipamorelin copies a separate order that’s tied to hunger. Your gland then lets out hormone it has already stored.
The orders can arrive together, which may make the rise larger. Your liver responds by making IGF-1, a blood protein tied to growth.
Ipamorelin may also loosen your body’s natural brake on the hormone. You can see both routes on the growth hormone secretagogue page.
Did two messages raise more growth hormone?
This 30-year-old finding came from only 18 healthy men. That’s too small and narrow to answer for you or everyone else.
Each man received drugs that copied both natural messages [3]. Growth hormone rose more with the two than with either one alone.
The men didn’t receive CJC-1295 or the fixed CJC-1295 Ipamorelin pair. The amounts of the two study drugs were 0.1 and 0.3 micrograms per kilogram, plus 1 microgram per kilogram of the first message.
A later test used changed cells in a dish, not people. You can see about twice the response when both routes were active [4].
These studies explain why the drugs are paired. They don’t show what long use of the fixed pair does to you.
Why does CJC-1295 DAC stay for days?
The work began in rats and later moved to healthy adults. CJC-1295 carries a small added tag called DAC.
The tag lets the drug cling to albumin, a carrier protein in your blood. In rats, total growth hormone reached about 4-fold—four times—the level seen with the short natural message.
Researchers still found the tagged drug in rat blood beyond 72 hours [5]. Later, healthy adults got one shot beneath the skin.
Their average hormone level rose 2 times at the low end and 10-fold—ten times—at the high end through six days and beyond. IGF-1, a growth-related blood protein, rose 1.5 times at the low end and 3-fold—three times—at the high end for 9 to 11 days.
After repeat shots, IGF-1 remained above its start for up to 28 days [1]. The tag also protects the drug from an enzyme in your blood that clears the natural message fast.
That’s the key difference with cjc 1295 dac. Your blood holds it for days instead of minutes.
What is Mod GRF 1-29, the short CJC-1295?
Mod grf 1-29 is CJC-1295 without the blood-holding tag. It copies the same natural message but can’t cling to albumin.
Its 30-minute half-life means about half the drug is gone by then. Your blood breaks it down fast, so the hormone rise is brief.
The tagged CJC-1295 keeps one message going for days. Mod GRF 1-29 gives short rises that sit closer to your body’s usual rhythm.
The two forms share a base but don’t stay in your body alike. Confusing them can leave you with the wrong idea about timing.
Why did researchers pick ipamorelin?
The key study used pigs, so its answer may not fit you. Ipamorelin lifted growth hormone without also lifting the pigs’ stress hormones.
That remained true above 200 times the least amount that caused a rise. It worked about as well as an older drug called GHRP-6 [2].
Older drugs called GHRP-6 and GHRP-2 also raised stress hormones. Ipamorelin had a narrower effect in these pigs.
Researchers often picked it for the second message because of that result. Even so, a pig test can’t tell you how the fixed pair would affect you.
What changed in the rats’ bones?
All the bone studies here used animals. You can’t get a human dose or a sure result from them.
Bone in adult female rats grew from about 42 to about 52 micrometers per day over 15 days [8]. Another study used three daily amounts of 100 micrograms per kilogram and found less bone loss from steroid drugs.
New bone formed at four-fold the rate seen with the steroid alone [9]. Over 12 weeks, 0.5 milligrams per kilogram per day raised bone mineral in adult female rats [10].
The older comparison drug GHRP-6 did the same. Other work found that more growth hormone can help your body build new protein [11].
The rats’ bones changed after the hormone rose. You can’t assume that your bones would act the same way.
Ipamorelin vs sermorelin: how do they differ?
CJC-1295, ipamorelin, and sermorelin don’t give the growth gland the same order. Sermorelin copies the first natural message, while ipamorelin copies the hunger-linked one [2].
So ipamorelin vs sermorelin isn’t a clean head-to-head match. Each drug has a separate job.
When both message types were given, the men’s growth hormone climbed farther [3]. That’s why either CJC-1295 or sermorelin may be joined with ipamorelin.
I wouldn’t ask which one wins. I’d ask whether either drug has proof that fits your health question.
Ipamorelin vs tesamorelin: which has human proof?
Tesamorelin has stronger proof in people, though it works unlike ipamorelin. A 2026 review brought together five fair tests of tesamorelin.
Fat around the inner organs shrank by an average of 27.71 square centimeters, and fat in the liver fell 4.28%. Lean body weight rose 1.42 kilograms, along with IGF-1, the growth-related blood protein.
The review found no life-threatening harm or worse blood sugar in those tests [7]. For ipamorelin, most results still come from rats [2][8].
CJC-1295 sends yet another order to the growth gland. You can’t hand tesamorelin’s results to this pair.
Where does the proof in people end?
CJC-1295 reached Phase 2, a mid-stage human test, and then the work ended. Why it ended isn’t stated in the papers used here.
Earlier Phase 1 studies were small first tests in healthy adults. They measured how long the drug stayed and how the amount changed growth hormone [1].
Ipamorelin was also studied for bowels that stop after surgery. It hasn’t won approval.
Researchers haven’t published a human test of ready-mixed CJC-1295 Ipamorelin. Claims about the pair rest on separate work and older tests of the two natural messages.
A 2026 review found hints that ipamorelin might help muscle or injury, but no strong human trial proved a benefit. The review warned that unapproved peptide drugs can cause serious harm when their contents and long-term effects aren’t known [14].
That’s where the human proof ends. You shouldn’t have to guess how much remains unknown.